These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23402998)

  • 1. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.
    Stearns-Kurosawa DJ; Oh SY; Cherla RP; Lee MS; Tesh VL; Papin J; Henderson J; Kurosawa S
    Am J Pathol; 2013 Apr; 182(4):1227-38. PubMed ID: 23402998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.
    Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli.
    Stearns-Kurosawa DJ; Collins V; Freeman S; Tesh VL; Kurosawa S
    Infect Immun; 2010 Jun; 78(6):2497-504. PubMed ID: 20308301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.
    Lee BC; Mayer CL; Leibowitz CS; Stearns-Kurosawa DJ; Kurosawa S
    Blood; 2013 Aug; 122(5):803-6. PubMed ID: 23733336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.
    Petruzziello-Pellegrini TN; Yuen DA; Page AV; Patel S; Soltyk AM; Matouk CC; Wong DK; Turgeon PJ; Fish JE; Ho JJ; Steer BM; Khajoee V; Tigdi J; Lee WL; Motto DG; Advani A; Gilbert RE; Karumanchi SA; Robinson LA; Tarr PI; Liles WC; Brunton JL; Marsden PA
    J Clin Invest; 2012 Feb; 122(2):759-76. PubMed ID: 22232208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
    Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
    J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.
    Shimizu M
    Pediatr Int; 2020 Mar; 62(3):308-315. PubMed ID: 31742829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS
    J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells.
    Legros N; Pohlentz G; Steil D; Müthing J
    Int J Med Microbiol; 2018 Dec; 308(8):1073-1084. PubMed ID: 30224239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation.
    Jandhyala DM; Ahluwalia A; Schimmel JJ; Rogers AB; Leong JM; Thorpe CM
    Infect Immun; 2016 Jan; 84(1):138-48. PubMed ID: 26483408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.
    Miceli S; Jure MA; de Saab OA; de Castillo MC; Rojas S; de Holgado AP; de Nader OM
    Jpn J Infect Dis; 1999 Apr; 52(2):33-7. PubMed ID: 10816611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.
    Tremblay JM; Mukherjee J; Leysath CE; Debatis M; Ofori K; Baldwin K; Boucher C; Peters R; Beamer G; Sheoran A; Bedenice D; Tzipori S; Shoemaker CB
    Infect Immun; 2013 Dec; 81(12):4592-603. PubMed ID: 24082082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.
    Ludwig K; Sarkim V; Bitzan M; Karmali MA; Bobrowski C; Ruder H; Laufs R; Sobottka I; Petric M; Karch H; Müller-Wiefel DE
    J Clin Microbiol; 2002 May; 40(5):1773-82. PubMed ID: 11980959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.
    Brandelli JR; Griener TP; Laing A; Mulvey G; Armstrong GD
    Toxins (Basel); 2015 Oct; 7(10):4054-66. PubMed ID: 26473922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic
    Tasaki Y; Inoue N; Shimizu M; Sugimoto N; Ishikawa S; Mizuta M; Yokoyama T; Kuroda M; Ohta K; Yachie A; Wada T
    Ren Fail; 2021 Dec; 43(1):382-387. PubMed ID: 33641616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in pathogenesis and therapy of hemolytic uremic syndrome caused by Shiga toxin-2.
    Ibarra C; Amaral MM; Palermo MS
    IUBMB Life; 2013 Oct; 65(10):827-35. PubMed ID: 24014500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2.
    Jeong KI; Tzipori S; Sheoran AS
    J Infect Dis; 2010 Apr; 201(7):1081-3. PubMed ID: 20196656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.
    Bentancor LV; Mejías MP; Pinto A; Bilen MF; Meiss R; Rodriguez-Galán MC; Baez N; Pedrotti LP; Goldstein J; Ghiringhelli PD; Palermo MS
    mBio; 2013 Oct; 4(5):e00501-13. PubMed ID: 24085779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.